Navigation Links
Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
Date:8/29/2010

PARIS, Aug. 29 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has submitted a non-binding proposal to acquire Genzyme (Nasdaq: GENZ) in an all-cash transaction valued at approximately $18.5 billion.

Under the terms of the proposed acquisition, Genzyme shareholders would receive $69 per Genzyme share in cash, representing a 38% premium over Genzyme's unaffected share price of $49.86 on July 1, 2010. Sanofi-aventis' offer also represents a premium of almost 31% over the one-month historical average share price through July 22, 2010, the day prior to press speculation that sanofi-aventis had made an approach to acquire Genzyme. Based on analyst consensus estimates, the offer represents a multiple of 36 times Genzyme's 2010 earnings per share and 20 times 2011 earnings per share. Accordingly, the offer price takes into account the upside potential of the anticipated recovery in Genzyme's performance in 2011. Sanofi-aventis has secured financing for its offer.

The non-binding offer, which was made on July 29, 2010, was reiterated in a letter sent today to Genzyme's Chairman, President and Chief Executive Officer, Henri A. Termeer, after several unsuccessful attempts to engage Genzyme's management in discussions. Sanofi-aventis is disclosing the contents of its letter in order to inform Genzyme's shareholders of the significant shareholder value and compelling strategic fit inherent in a combination of the two companies.

Genzyme is a leading bio-pharmaceutical company based in Cambridge, Massachusetts. Its products address rare diseases, kidney disease, orthopedics, cancer, transplant and immune diseases, and diagnostic testing.  Sanofi-aventis' global reach and significant resources would allow Genzyme to accelerate investment in new
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
2. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
3. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
4. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
5. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
6. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
7. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
8. Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector
9. Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America
10. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
11. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 IRIDEX Corporation (NASDAQ: ... second quarter 2015 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, August 6, 2015 ... other business developments. Interested parties may access ...
(Date:7/30/2015)... 30, 2015  Unichem Pharmaceuticals ( USA ... Hydrochlorothiazide tablets 25 mg 1000-count bottle to the consumer ... measure due to the identification of a Clopidogrel tablet ... The risk associated with mistakenly taking a Clopidogrel ... probability of experiencing Clopidogrel,s side effects which include bleeding ...
(Date:7/30/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... regarding the notice it received on May 21, 2015 ... the Company was below certain of the Exchange,s continued ... 1101 of the NYSE MKT Company Guide, due to ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
...   Unigene Laboratories, Inc. (OTCBB: UGNE), today announced ... position of Chief Financial Officer. In this newly created position, ... company,s executive leadership team and lead the strategic direction ... Mr. Moskowitz joins Unigene after spending the previous ...
... 2012 Reportlinker.com announces that a new ... catalogue: Vaccines - ... This market research report package offers ... situation, trends and future outlook for vaccines ...
Cached Medicine Technology:Unigene Appoints David Moskowitz as Chief Financial Officer 2Unigene Appoints David Moskowitz as Chief Financial Officer 3Unigene Appoints David Moskowitz as Chief Financial Officer 4Unigene Appoints David Moskowitz as Chief Financial Officer 5Vaccines - Asia 2
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca ... on the go. With no water needed, the refreshing berry-flavored tablets are the ... to get the natural ingredients that may help with body detoxification, protection and ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Mid-Atlantic region, is the recipient of three awards in the Service Industry Advertising ... programs created for Choptank Transport, KRM Development Corporation and University of Maryland Shore ...
(Date:7/30/2015)... ... 30, 2015 , ... Well-known San Diego AC, plumbing and ... cost service and repair companies. For 35 years, they have grown both their ... to meet the demands of the changing technological environment. , To ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a ... San Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) have awarded ... health care providers. 24/7 Care At Home’s agency is one of three top Orange ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... Institute Scholar Program. In partnership with Patient Experience Institute, these offerings reinforce the ... on the front lines and throughout the experience movement, and provide information and ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3
... function problems in ill veterans , , TUESDAY, March 24 ... 1991 Gulf War appears to have triggered abnormal responses ... found. , They say the discovery could lead to ... Gulf War syndrome. , The study, from the ...
... eating fish, study finds , , TUESDAY, March 24 (HealthDay ... against advanced prostate cancer, researchers report. , Eating fish ... of developing advanced prostate cancer even if one is ... is needed to see if the association is real, ...
... against advanced prostate cancer, and this effect may be ... according to a report in Clinical Cancer Research ... Research. , "Previous research has shown protection against prostate ... to show protection against advanced prostate cancer and interaction ...
... YORK, March 24, 2009 Researchers may have found a more ... history of the deadly skin disease. In a new study, scientists ... to a nearly four-fold increase of melanoma in women under the ... 24, 2009, in the journal Clinical Cancer Research and ...
... WASHINGTONThe World Health Organization released staggering new data about the ... with HIV/AIDS today, in recognition of World TB Day. ... previously thought, the new WHO figures show. In 2007, there ... 15 percent of the total incident cases. That,s double the ...
... students who are problem drinkers using alcohol to cope ... to continue excessive drinking into adulthood, a recent study ... that adults who are still high-risk drinkers by age ... social and cognitive development that typically occurs during college, ...
Cached Medicine News:Health News:Gulf War Syndrome May Stem From Chemical Exposure 2Health News:Omega-3 Fatty Acids Guard Against Advanced Prostate Cancer 2Health News:Omega-3 Fatty Acids Guard Against Advanced Prostate Cancer 3Health News:NYU study finds new risk factor for melanoma in younger women 2Health News:NYU study finds new risk factor for melanoma in younger women 3Health News:Alarming new data shows TB-HIV co-infection a bigger threat 2Health News:Study helps identify college drinkers who might continue excessive drinking as adults 2Health News:Study helps identify college drinkers who might continue excessive drinking as adults 3Health News:Study helps identify college drinkers who might continue excessive drinking as adults 4Health News:Study helps identify college drinkers who might continue excessive drinking as adults 5
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
The Secur-Fit cups incorporate enhancements derived from years of clinical, radiographic, and implant retrieval observations....
The Bofor acetabular revision cup addresses cases of severe acetabular destruction....
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Medicine Products: